The reduction in TAZ caused by RANKL activation can be reversed by MG132 (a 26S proteasome inhibitor), suggesting that TAZ, a downstream signaling molecule in the Hippo signaling pathway, may be a new target for the treatment of osteoporosis. This evidence concerns the gene WWTR1 and osteoporosis.